The BIOAF chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the BIOAF chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.
The BIOAF stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.
|View BIOAF Detailed Price Forecast - CNN Money||View BIOAF Detailed Summary - Google Finance|
|View BIOAF Detailed Summary - Yahoo! Finance||View BIOAF Stock Research & Analysis - Zacks.com|
|View BIOAF Trends & Analysis - Trade-Ideas||View BIOAF Major Holders - Barrons|
|View BIOAF Call Transcripts - NASDAQ||View BIOAF Breaking News & Analysis - Seeking Alpha|
|View BIOAF Annual Report - CompanySpotlight.com||View BIOAF OTC Short Report - OTCShortReport.com|
|View BIOAF Fundamentals - TradeKing||View BIOAF SEC Filings - Bar Chart|
|View Historical Prices for BIOAF - The WSJ||View Performance/Total Return for BIOAF - Morningstar|
|View the Analyst Estimates for BIOAF - MarketWatch||View the Earnings History for BIOAF - CNBC|
|View the BIOAF Earnings - StockMarketWatch||View BIOAF Buy or Sell Recommendations - MacroAxis|
|View the BIOAF Bullish Patterns - American Bulls||View BIOAF Short Pain Metrics - ShortPainBot.com|
|View BIOAF Stock Mentions - StockTwits||View BIOAF Stock Mentions - PennyStockTweets|
|View BIOAF Stock Mentions - Twitter||View BIOAF Investment Forum News - Investor Hub|
|View BIOAF Stock Mentions - Yahoo! Message Board||View BIOAF Stock Mentions - Seeking Alpha|
|View Insider Transactions for BIOAF - SECform4.com||View Insider Transactions for BIOAF - Insider Cow|
|View BIOAF Major Holdings Summary - CNBC||View Insider Disclosure for BIOAF - OTC Markets|
|View Insider Transactions for BIOAF - Yahoo! Finance||View Institutional Holdings for BIOAF - NASDAQ|
|View BIOAF Stock Insight & Charts - FinViz.com||View BIOAF Investment Charts - StockCharts.com|
|View BIOAF Stock Overview & Charts - BarChart||View BIOAF User Generated Charts - Trading View|
Bioasis Announces Non-Brokered Private Placement
Posted on Monday July 16, 2018
OTCQB:BIOAF) (“Bioasis” or the “Company”), a biopharmaceutical company developing its xB3 proprietary platform technology for the delivery of therapeutics across the blood-brain barrier (BBB) for the treatment of CNS disorders, today announced that it intends to pursue a non-brokered private placement of units (the "Units") at a price of C$0.552 per Unit, for aggregate gross proceeds of up to C$3 million.
Bioasis and BioAgilytix Announce Strategic Collaboration to Advance xB3 TM-001, Bioasis’ Lead Investigational Candidate to Treat HER2+ Brain Cancer, to IND Submission and into the Clinic
Posted on Wednesday July 11, 2018
OTCQB:BIOAF), a biopharmaceutical company developing its xB3 TM proprietary platform technology for the delivery of therapeutics across the blood-brain barrier (BBB) and the treatment of CNS disorders, and BIOAGILYTIX, a leading provider of contract bioanalytical testing services with specialization in large molecule bioanalysis, today announced a strategic collaboration to partner on the development and validation of bioanalytical methods to support and advance the xB3 TM-001 program, Bioasis’ lead candidate to treat HER2+ brain cancer, to investigational new drug (IND) submission and into the clinic. The development and validation of bioanalytical methods are critical to ensuring the highest quality data to support regulatory approval of the IND and clinical pharmacokinetic data that will allow the Company to define the clinical dose for the program to ensure maximum therapeutic benefit for patients in Phase 1 and beyond.
Bioasis Announces Filing of Its Fourth Quarter and Fiscal Year-End Financial Statements and MD&A
Posted on Tuesday June 26, 2018
BIOASIS TECHNOLOGIES INC. , a biopharmaceutical company developing its xB3 TM proprietary platform technology for the delivery of therapeutics across the blood-brain barrier and the treatment of CNS disorders in areas of high unmet medical need, including brain cancers and neurodegenerative diseases, today announced that it has filed its fourth quarter and annual audited consolidated financial statements ...
BiOasis: Fiscal 4Q Earnings Snapshot
Posted on Tuesday June 26, 2018
On a per-share basis, the Richmond, British Columbia-based company said it had a loss of 4 cents. The biotech drug developer posted revenue of $71,300 in the period. Its adjusted revenue was $71,000. For ...